PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26022F0237Arcalyst rilonacept 220mg VIL INJ — Kiniksa Pharmaceuticals (Uk), Ltd

Kiniksa Pharmaceuticals (Uk), Ltd holds $1.2M across 22 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 1 related award under parent 36F79722D0002. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended May 31, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

260-Network Contract Office 20 (36C260)

Awarding office

Kiniksa Pharmaceuticals (Uk), Ltd

Recipient

May 31, 2023

PoP end

$195K

Obligated

$195K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Kiniksa Pharmaceuticals (Uk), Ltd — $90

Contract facts

Federal

Contract number36C26022F0237

Also listed as36C260-22-F-0237

Also listed as36F79722D0002-36C26022F0237

Agency260-Network Contract Office 20 (36C260)

Awarding office260-Network Contract Office 20 (36C260)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentKiniksa Pharmaceuticals (Uk), Ltd

CAGEU1S38

UEIHBHWNLNMHSV5

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79722D0002

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startApr 6, 2022

PoP end (current)May 31, 2023

Obligated$195K

Current value$195K

Potential value$195K

RILONACEPT (ARCALYST) 220MG/VIL INJ is a federal award for 260-Network Contract Office 20 (36C260) held by Kiniksa Pharmaceuticals (Uk), Ltd. Estimated value $195K ($195K obligated). Current period of performance ends May 31, 2023. Last award drew 1 bidder.

Recompete timing

Public

● Past PoP end (1178 days ago)

Current PoP ended May 31, 2023 (1178 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Kiniksa Pharmaceuticals (Uk), Ltd — $1.2M obligated across 22 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($1.2M) · all agencies

Department of Veterans Affairs (VA)$942K · 79%Department of Justice (DOJ)$269K · 22%

Open full company profile →

Related awards

Same parent · incumbent

36C26026F0076

BULK - ARCALYST 220MG VIL

$220K

Dec 14, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26022F0237?

36C26022F0237 (Arcalyst rilonacept 220mg VIL INJ) is a 260-Network Contract Office 20 (36C260) award with a potential value of $195K, currently held by Kiniksa Pharmaceuticals (Uk), Ltd. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-22-F-0237?

36C260-22-F-0237 is the dashed form of PIID 36C26022F0237 (Arcalyst rilonacept 220mg VIL INJ), held by Kiniksa Pharmaceuticals (Uk), Ltd. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26022F0237?

260-Network Contract Office 20 (36C260) awarded 36C26022F0237 to Kiniksa Pharmaceuticals (Uk), Ltd (potential $195K).

Who is the incumbent on 36C26022F0237?

Kiniksa Pharmaceuticals (Uk), Ltd is the incumbent with $1.2M across 22 related awards in SCOUT’s public footprint. The current period of performance ends May 31, 2023.

When does Kiniksa Pharmaceuticals (Uk), Ltd’s 36C26022F0237 come up for recompete?

SCOUT tracks a period-of-performance end of May 31, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Jun 29, 2023